6 OVERVIEW

7 KEY TAKEAWAYS

8 DISEASE BACKGROUND

8 PTCL subtypes

10 TREATMENT

11 EPIDEMIOLOGY

16 MARKETED DRUGS

19 PIPELINE DRUGS

24 RECENT EVENTS AND ANALYST OPINION

24 Copiktra for PTCL (July 25, 2019)

24 Sintilimab for PTCL (May 15, 2019)

26 Copiktra for PTCL (March 6, 2019)

27 Multiple Drugs for PTCL (January 17, 2019)

28 Copiktra for PTCL (December 3, 2018)

30 Tipifarnib (Oncology) for PTCL (December 2, 2018)

31 Adcetris for PTCL (October 1, 2018)

33 Cerdulatinib for PTCL (June 4, 2018)

36 KEY UPCOMING EVENTS

37 KEY REGULATORY EVENTS

37 Adcetris Speeds To PTCL Approval With Two-Week Review

38 PROBABILITY OF SUCCESS

39 LICENSING AND ASSET ACQUISITION DEALS

39 Ono Licenses Rafael’s Novel Chemo-Sensitizing Agent For Asia

40 PARENT PATENTS

41 REVENUE OPPORTUNITY

42 CLINICAL TRIAL LANDSCAPE

43 Sponsors by status

44 Sponsors by phase

45 Recent events

46 BIBLIOGRAPHY

46 Prescription information

47 APPENDIX

LIST OF FIGURES

13 Figure 1: Trends in incident cases of PTCL, 2017–26

15 Figure 2: Incident cases of PTCL, by age, 2017

19 Figure 3: Overview of pipeline drugs for PTCL in the US

19 Figure 4: Pipeline drugs for PTCL, by company

20 Figure 5: Pipeline drugs for PTCL, by drug type

20 Figure 6: Pipeline drugs for PTCL, by classification

26 Figure 7: Sintilimab for PTCL (May 15, 2019): Phase II - ORIENT-4

30 Figure 8: Copiktra for PTCL (December 3, 2018): Phase I - w/Romidepsin or Bortezomib (TCLs) (MSKCC)

31 Figure 9: Tipifarnib (Oncology) for PTCL (December 2, 2018): Phase II - 002

33 Figure 10: Adcetris for PTCL (October 1, 2018): Phase III - ECHELON-2

35 Figure 11: Cerdulatinib for PTCL (June 4, 2018): Phase I/IIa - Two Part Dose Escalation

36 Figure 12: Key upcoming events in PTCL

38 Figure 13: Probability of success in the PTCL pipeline

39 Figure 14: Licensing and asset acquisition deals in PTCL, 2014–19

40 Figure 15: Parent patents in PTCL

42 Figure 16: Clinical trials in PTCL

42 Figure 17: Top 10 drugs for clinical trials in PTCL

43 Figure 18: Top 10 companies for clinical trials in PTCL

43 Figure 19: Trial locations in PTCL

44 Figure 20: PTCL trials status

45 Figure 21: PTCL trials sponsors, by phase

LIST OF TABLES

12 Table 1: Incident cases of PTCL, 2017–26

14 Table 2: Incident cases of PTCL, by gender, 2017

17 Table 3: Marketed drugs for PTCL

21 Table 4: Pipeline drugs for PTCL in the US

24 Table 5: Copiktra for PTCL (July 25, 2019)

25 Table 6: Sintilimab for PTCL (May 15, 2019)

27 Table 7: Copiktra for PTCL (March 6, 2019)

28 Table 8: Multiple Drugs for PTCL (January 17, 2019)

29 Table 9: Copiktra for PTCL (December 3, 2018)

30 Table 10: Tipifarnib (Oncology) for PTCL (December 2, 2018)

32 Table 11: Adcetris for PTCL (October 1, 2018)

34 Table 12: Cerdulatinib for PTCL (June 4, 2018)

41 Table 13: Historical global sales, by drug ($m), 2014–18
41 Table 14: Forecasted global sales, by drug ($m), 2019–23